AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Insilico’s CEO Makes the Case for AI as a Drug-Development Workflow, Not a Magic Box
In comments to STAT, Insilico Medicine’s leadership framed AI’s best use in drug development as a practical system for narrowing uncertainty, not replacing scientific judgment. That framing reflects a broader maturation in the sector as companies shift from grand claims to integrated, stage-specific deployment.
TechTarget’s Read on Lilly-Insilico Points to a New Enterprise Reality: AI Discovery Needs Fit, Not Just Promise
TechTarget’s coverage of Lilly’s expanded Insilico pact underscores a practical lesson for healthcare AI leaders: the value of AI drug discovery now depends on how it fits into enterprise R&D systems. The challenge is less about whether AI can generate candidates and more about whether pharma organizations can absorb, validate, and develop them efficiently.
Data infrastructure is emerging as the real bottleneck in AI drug discovery
A GEN analysis argues that the success of AI in drug discovery depends less on flashy models than on the quality, lineage and interoperability of underlying data systems. The article reinforces a growing industry reality: many AI failures in biopharma are infrastructure failures in disguise.
Contract Pharma’s Read on AI R&D Suggests Early Discovery Is Becoming a Workflow Engineering Problem
A new analysis of AI in early drug development argues that the field’s next phase will be decided by workflow design, not by model hype alone. The implication for biopharma is that durable advantage may come from integrating AI into experimental loops rather than treating it as a separate innovation layer.
Shuttle Pharma’s automation push reflects the next phase of AI in drug research: less glamour, more workflow reduction
Shuttle Pharma’s new AI initiative is aimed at reducing manual work in drug research, a more grounded use case than many headline-grabbing platform claims. The move illustrates how biotech adoption is shifting toward operational efficiency tools that can be validated in day-to-day R&D.
Shuttle Pharma Expands Its AI Discovery Platform, Underscoring AI’s Shift From Feature to Operating Layer
Shuttle Pharma’s platform expansion, as reported by Investing.com, reflects a broader market trend: AI is being positioned as an ongoing capability layer across discovery programs rather than a one-off tool. The move suggests more biopharma companies are trying to institutionalize AI inside their development operations.
AI Drug Discovery’s Real Challenge Is No Longer Prediction but Execution
A new CHEManager analysis argues that aligning AI with laboratory execution is now the central challenge in drug discovery. The point captures a broad industry turn: value increasingly depends on whether models can be embedded in reliable experimental loops, not merely whether they produce impressive in silico outputs.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.